ZFGN - Zafgen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.57
-0.10 (-1.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.67
Open9.65
Bid0.00 x 1400
Ask0.00 x 3200
Day's Range9.51 - 9.83
52 Week Range3.24 - 11.36
Volume90,722
Avg. Volume407,987
Market Cap352.23M
Beta-0.73
PE Ratio (TTM)N/A
EPS (TTM)-2.00
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Zafgen to Present at the Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 08, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • Associated Press7 days ago

    Zafgen: 2Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 57 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire7 days ago

    Zafgen Reports Second Quarter 2018 Operating and Financial Results

    Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome expected to begin in the fourth quarter 2018. Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation for Prader-Willi ...

  • ACCESSWIRE7 days ago

    Zafgen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Zafgen, Inc. (NASDAQ: ZFGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • Benzinga12 days ago

    The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...

  • GlobeNewswire12 days ago

    Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today that Thomas Hughes, Ph.D., has resigned from his role as President and Chief Scientific Officer at Zafgen to accept a Chief Executive Officer role at a privately held biotechnology company. Dr. Hughes is also stepping down from Zafgen’s Board of Directors. Dr. Hughes’s last day with Zafgen will be in the coming weeks and a search for a successor is underway.

  • GlobeNewswire13 days ago

    Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference

    BOSTON, Aug. 01, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • GlobeNewswire14 days ago

    Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results

    BOSTON, July 31, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • Harry Boxer’s three drug stocks to watch
    MarketWatch27 days ago

    Harry Boxer’s three drug stocks to watch

    Drug stocks are dominating our list of top charts to watch. Arbutus Biopharma Corp. (ABUS) snapped back 55 cents to $11.35 on 417,300 shares traded Tuesday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped 65 cents to $16.45 on 1 million shares traded Tuesday.

  • GlobeNewswirelast month

    Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, and the Foundation for Prader-Willi Research (FPWR), a nonprofit organization founded to eliminate the challenges of Prader-Willi syndrome (PWS) through the advancement of research and therapeutic development, announced today the launch of a co-sponsored natural history study to advance understanding of the medical history of and medical events in people with PWS. PATH for PWS (Paving the way for Advances in Treatments & Health for PWS) is a non-interventional, observational study of serious medical events in PWS, intended to inform development and clinical trial design for potential new treatments for PWS, including ZGN-1258, Zafgen’s new, second-generation program for PWS designed to decrease hyperphagia, change the way the body metabolizes fat, and reduce fat mass.

  • Zafgen (ZFGN) Surges: Stock Moves 9.2% Higher
    Zackslast month

    Zafgen (ZFGN) Surges: Stock Moves 9.2% Higher

    Zafgen (ZFGN) shares rose more than 9% in the last trading session, amid huge volumes.

  • GlobeNewswirelast month

    Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares

    BOSTON, July 02, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool2 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these high-flying biotech stocks keep up their momentum?

  • Here's Why Zafgen Inc. Rose by Double Digits Today
    Motley Fool2 months ago

    Here's Why Zafgen Inc. Rose by Double Digits Today

    The early-stage biopharma announced the pricing of a common stock offering.

  • GlobeNewswire2 months ago

    Zafgen Announces Pricing of Offering of Common Stock

    BOSTON, June 28, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic ...

  • GlobeNewswire2 months ago

    Zafgen Announces Proposed Offering of Common Stock

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by Zafgen. In addition, Zafgen intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Exelixis and Zafgen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • GlobeNewswire2 months ago

    Zafgen Set to Join Russell 3000® Index

    BOSTON, June 25, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic ...

  • GlobeNewswire2 months ago

    REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call

    BOSTON, June 25, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, will ...

  • GlobeNewswire2 months ago

    Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today positive full results from the Company’s Phase 2 clinical trial of ZGN-1061, designed to demonstrate proof-of-concept efficacy and safety in patients with type 2 diabetes and establish a minimally effective dose. The trial met all of its primary endpoints at the 0.9 mg dose, and 12-week data demonstrated a favorable safety and tolerability profile, with no treatment-related serious adverse events and no CV safety signals observed. Data for this trial and two supportive nonclinical studies for ZGN-1061 are being presented as late-breaker abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida.

  • Benzinga2 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements.  ...

  • GlobeNewswire2 months ago

    Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors

    BOSTON, June 07, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic ...

  • GlobeNewswire3 months ago

    Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today the appointment of Brian McVeigh as Chief Business Officer. Mr. McVeigh joins Zafgen following a 25-year career with GlaxoSmithKline (GSK) where he held multiple senior-level positions within the global Business Development, Finance, Marketing, Corporate and R&D organizations.

  • Associated Press3 months ago

    Zafgen: 1Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 58 cents. Zafgen shares have climbed 60 percent since the beginning of the year. The stock has risen 54 percent in the last 12 months. ...